Public Company Edition: CG Oncology grossed $380m in the first biopharma IPO in the US in 2024. Follow-on offerings have been robust recently, with Edgewise and Immatics grossing $240m and $175m, respectively. 

The Danish firm’s CEO Claus Olesen tells Scrip that pudafensine could help the 35% of men who do not respond to the currently available treatments for ED.

The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.

Despite the growing interest, both in and outside of the biotech space, in the so-called ‘longevity’ industry, no regulatory pathway exists to market a drug with a purely geroprotective indication.